Familiarità e suscettibilità nelle neoplasie ematologiche Sindromi mieloproliferative familiari. Elisa Rumi
|
|
- Percival Copeland
- 6 years ago
- Views:
Transcription
1 Familiarità e suscettibilità nelle neoplasie ematologiche Sindromi mieloproliferative familiari lisa Rumi Dipartimento di matologia Oncologia Fondazione IRS oliclinico San Matteo avia Firenze 14 marzo 2013
2 Why hereditary predisposition to MN? Several lines of evidence: henotypic diversity of MN (, V, MF) despite a common somatic mutation (JK2 V617F) xistence of biclonal MN with 2 independent clones in the same patient ommon polymorphims predisposing to MN (JK2 haplotype) Familial clustering of MN
3 Hereditary predisposition to MN 1 st line of evidence: host modifying influences JK2 V617F Mouse model Balb/c 57Bl/6 Strain specific modifiers: Balb/c mice show markedly elevated WB count, splenomegaly, fibrosis compared to 57Bl/6 mice Werning et al, Blood 2006
4 Why hereditary predisposition to MN? Several lines of evidence: henotypic diversity of MN (, V, MF) despite a common somatic mutation (V617F JK2) xistence of biclonal MN with 2 independent clones in the same patient ommon polymorphims predisposing to MN (JK2 haplotype) Familial clustering of MN
5 Hereditary predisposition to MN 2 nd line of evidence: biclonal MN he mutation-bearing clones express different alleles of the X-linked SN (rs in IDS) the 2 mutations had arisen in unrelated hematopoietic stem cells: mutation-bearing clones are clonally unrelated Beer et al, BJH 2009
6 Why hereditary predisposition to MN? Several lines of evidence: henotypic diversity of MN (, V, MF) despite a common somatic mutation (V617F JK2) xistence of biclonal MN with 2 independent clones in the same patient ommon polymorphims predisposing to MN (JK2 haplotype) Familial clustering of MN
7 What haplotype is? Set of DN sequences (one or more loci or SN) very close along the chromosome hey tend to be inherited together due to absence of recombination during crossover (genetic linkage ) h"p://hapmap.ncbi.nlm.nih.gov/originhaplotype.html.en
8 Hereditary predisposition to MN 3 rd line of evidence: JK2 haplotype predisposing to MN 88% of all JK2-V617F mutations occur on the JK2 haplotype Olcaydu et al, Nat enet /1 is a significant constitutional risk factor for development of V617F positive MNs [OR =3.7; 95% I, ] Jones et al, Nat enet 2009 Not 46/1 1 46/
9 Role of the JK2 haplotype: 2 hypotheses Hypermutability: there is a specific mutational mechanism by which V617F preferentially arises on a 46/1 haplotype Fertile ground: mutation rate on 46/1 and non-46/1 haplotypes is the same but the probability of clinically manifest disease is higher if V617F arises on 46/1 ampbell, Nat enet 2009
10 Hereditary predisposition to MN 3 rd line of evidence: JK2 haplotype predisposing to MN he JK2 haplotype predisposes: to JK2-exon 12 mutated MN to M-mutated MN to and MF independently from JK2 status he JK2 haplotype is the major common genetic susceptibility factor for MN Olcaydu et al, eukemia 2009 Jones et al, Blood 2010 ardanani et al, eukemia 2010 efferi et al, eukemia 2010
11 Why hereditary predisposition to MN? Several lines of evidence: henotypic diversity of MN (, V, MF) despite a common somatic mutation (V617F JK2) xistence of biclonal MN with 2 independent clones in the same patient ommon polymorphims predisposing to MN (JK2 haplotype) Familial clustering of MN
12 Hereditary predisposition to MN 4 th line of evidence: familial clustering of MN Familial clustering in 7.6% of apparently sporadic MN Relatives of MN patients have a 5- to 7- fold increased risk of developing MN Rumi et al, JO 2007 andgren et al, Blood 2008
13 Familial clustering of MN: pathogenesis he known recurrent MN-associated mutations (JK2, M, 2, B) are acquired as somatic mutations also in familial MN genetic predisposition to acquisition of different JK2 mutations may be inherited I:1 I:2 Olcaydu et al, Haematologica 2011 ietra et al, Blood 2008 * * * II:1 II:3 II:5 JK2 V617F-pos V V II:7 JK2 xon 12-pos 2-pos
14 Familial clustering of MN: pathogenesis frequency in % JK2 haplotype frequency control sporadic MN familial MN he haplotype frequency was higher in familial (0.44) and sporadic (0.42) MN than in control (0.27) Familial MN did not differ significantly from sporadic MN in disease risk conferred by the haplotype ( ns) Olcaydu et al, Haematologica 2011
15 Familial clustering of MN: clinical phenotype linical phenotype may be homogeneous (all relatives affected have the same MN) or mixed (different MNs in the same pedigree) llele burden varies among MNs Rumi et al, JO 2007
16 Familial clustering of MN: clinical phenotype at diagnosis ge, years Median Range Sex Male Female WB, x10 9 /l Median Range Hb, g/dl Median Range x10 9 /l Median Range Familial V (n=36) Sporadic V (n=188) Familial (n=24) Sporadic (n=157) Familial MF (n=15) Sporadic MF (n=78) Splenomegaly, No. (%) 7 (19) 47 (25) (8) 3 (2) (60) 48 (62) 0.1 hrombosis, No. (%) 10 (28) 44 (23) (8) 23 (14) (20) 12 (15) 0.7 Hemorrhage, No. (%) 1 (3) 15 (8) (4) 5 (3) (6) Familial MN similar to sporadic MN Rumi et al, JO 2007
17 Familial clustering of MN: complications high JK2 V617F allele burden is correlated with evolution to myelofibrosis in familial V (p<0.0001) and has a trend in familial (p=0.09) Malak et al, Blood ell Mol and Dis 2012
18 Familial clustering of MN: overall survival 100%; V 83%; MF 56% V 83% 83% V 37% 57% Rumi et al, JO 2007 Malak et al, Blood ell Mol and Dis 2012
19 Familial clustering of MN: differential diagnosis Hereditary thrombocytosis/ erythrocytosis Familial MN 1. olyclonal hematopoiesis 2. Mendelian inheritance 3. M, HO, OR mutations are disease causing genes 1. lonal hematopoiesis 2. omplex inheritance 3. JK2 mutations are secondary genetic events po receptor O2 sensing O2 affinity HO M rythrocytosis hrombocytosis ssential thrombocythemia olycythemia vera rimary myelofibrosis
20 Hereditary rythrocytosis Inheritance po Mechanism rimitive rythrocytosis F D ow runcated po Rec Secondary rythrocytosis O 2 sensing pathway defects: VH mutation R High VH mutation HD2 mutation HIF2α mutation D D Inapp high High HD2 mutation HIF2α mutation Hb with altered O 2 affinity: Hb variants with high affinity 2,3-D deficiency D D-R High High lobin chain mutations nzymatic defects
21 po Hereditary rythrocytosis: F (rimary familial and congenital polycythemia) 16 different mutations diverse affecting por cause truncation of the po receptor S por JK2 JK2 S S SH1 he inhibitory control is lost; continuous activation of JK2 and S S S Nucleus Kralovics et al. N ngl J Med 2005; 352: ; James et al. Nature 2005; 434:1144-8; Baxter et al. ancet 2005; 365: ; evine et al. ancer ell 2005; 7:387-97
22 Hereditary rythrocytosis : F (rimary familial and congenital polycythemia) High hemoglobin ow serum po bsence of splenomegaly Headache, dizziness Rare thromboses bsence of leukemic evolution utosomal dominant inheritance
23 Hereditary rythrocytosis Inheritance po Mechanism rimitive rythrocytosis F D ow runcated po Rec Secondary rythrocytosis O 2 sensing pathway defects: VH mutation R High VH mutation HD2 mutation HIF2α mutation D D Inapp high High HD2 mutation HIF2α mutation Hb with altered O 2 affinity: Hb variants with high affinity 2,3-D deficiency D D-R High High lobin chain mutations nzymatic defects
24 Hereditary rythrocytosis : O 2 sensing pathway defects (VH, HD, HIFα mutations) Normoxia Hypoxia rg200rp Ub ly537rp VH HIFα O O 2 HIFα 2 HIFα HD Formation of the HIFα-VH complex HD hydroxilates HIFα ro317rg HIFα HIFα HIFα HIFα Intracitoplsmic accumulation of HIFα and nuclear translocation Nucleus VH Ub HIFα proteasomal degradation Degradation of HIFα is impaired; continuous transcription of O po HIFα HR HIFβ Increased transcription of po gene in the kidney
25 Hereditary rythrocytosis: O 2 sensing pathway defects (VH, HD, HIFα mutations) ndemic in huvash Republic and Ischia; frequency of the 598 allele: - huvashia: Ischia: Worldwide Haplotype of Ischia patients=haplotype of huvash cluster single-founder hypothesis utosomal recessive inheritance (VH), utosomal dominant inheritance (HD, HIFα) High hemoglobin, po normal-high Young age, early mortality due to cerebral vascular events and peripheral thrombosis
26 huvash olycythemia: case report 36 yr, Hb 25 g/dl, splenomegaly Normal 50, po 115 mu/ml JK2 V617F and exon 12 neg Bone marrow biopsy not consistent with V Reference MN R W R200W Reference -y R200W R W avia unpublished data
27 ? M13_20 (..) Reference -y R MN W/R W/R VH R200 M12_570 (D..) Reference -y R MN W VH R200 R MN -y W M12_569 (D..) Reference R R MN -y R M12_568 (D.N.) Reference VH R200 W/R W/R VH R200 M13_21 (I..) Reference -y R MN R avia unpublished data -y VH R200 MN R R M13_22 (I.R.) Reference W/R W/R VH R200
28 Hereditary rythrocytosis Inheritance po Mechanism rimitive rythrocytosis F D ow runcated po Rec Secondary rythrocytosis O 2 sensing pathway defects: VH mutation R High VH mutation HD2 mutation HIF2α mutation D D Inapp high High HD2 mutation HIF2α mutation Hb with altered O 2 affinity: Hb variants with high affinity 2,3-D deficiency D D-R High High lobin chain mutations nzymatic defects ercy et al, JH 2009
29 Hereditary rythrocytosis : High affinity of Hb for O 2 (High-oxigen-affinity haemoglobinopathy, 2,3 D deficiency ) Hypoxia Dissociation curve shifts left less oxigen delivery to tissues High-oxigen-affinity Hb 2,3 D deficiency HIFα HIFα HIFα HIFα HIFα O 2 ytoplasmic accumulation of HIFα and nuclear translocation Nucleus Decreased delivery of oxigen to tissues; continuous transcription of O HIFα HR HIFβ Increased transcription of po in the kidney po
30 Hereditary rythrocytosis: altered affinity of Hb for O 2 (High-oxigen-affinity haemoglobinopathy, 2,3 D deficiency) 50 : partial pressure of O 2 at which 50% of Hb is saturated with oxigen (26 mmhg). High affinity hemoglobin and 2,3 D deficiency shift the curve leftward, thus reducing 50 Hb High affinity Hb 2,3 D deficiency
31 High affinity hemoglobin: case report 55 yr, Hb 17.7 g/dl mmhg (reduced) JK2 V617F and exon 12 neg Hb San Diego Rumi et al, JIM 2008
32 Hereditary thrombocytosis O HO M S505N S M JK2 JK2 S S Rare utosomal dominant inheritance: family history HO or M mutations S S Nucleus
33 Familial MN: JK2 germline mutations / / / Recent observation of new germline JK2 mutations: V617I, R564Q, H608N Mead et al, NJM 2012 theridge et al, SH 2011 Rumi et al, H 2012
34 onclusions Harutyunyan et al, Hematol Oncol lin North m. 2012
35 cknowledgements Department of Hematology Oncology Fondazione IRS oliclinico S. Matteo Università di avia Mario azzola manuela Boveri Ilaria asetti ristiana ascutto Daniela ietra enter for Molecular Medicine (emm) Vienna Robert Kralovics shot Harutyunyan Jelena Milosevic na uda Division of Hematology zienda ospedaliera universitaria Fondazione Macchi Varese Francesco assamonti
Prognostic models in PV and ET
Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis
More informationCooperation of germ line JAK2 mutations E846D and R1063H leads to erythroid hyperplasia with megakaryocytic atypia
Cooperation of germ line JAK2 mutations E846D and R1063H leads to erythroid hyperplasia with megakaryocytic atypia Katarina Kapralova, Ph.D. Department of Biology Faculty of Medicine and Dentistry Palacký
More informationUnderstanding Your Blood Work Results
Understanding Your Blood Work Results Carlos Besses, MD, hd Hematology Department Hospital del Mar - IMIM, Barcelona Carlos Besses Disclosures Novartis Honorarium Speaker Shire Honorarium Speaker Galena
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationPolycythemia Vera and Essential Thombocythemia A Single Institution Experience
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA
More informationThe Internists Approach to Polycythemia and Implications of Uncontrolled Disease
The Internists Approach to Polycythemia and Implications of Uncontrolled Disease Mary Jo K. Voelpel, DO, FACOI, MA, CS Associate Clinical Professor MSU-COM Disclosures NONE Overview 1. Objectives 2. Case
More informationBiologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche
41 CONGRESSO NAZIONALE SIE Bologna 14-17 Ottobre 2007 Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche Alessandro M. Vannucchi Dip.. di Ematologia, Università degli Studi
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationMolecular aberrations in MPN. and use in the clinic. Timothy Devos MD PhD
Molecular aberrations in MPN and use in the clinic Timothy Devos MD PhD MB&C2017 24-3-2017 Introduction 1951: William Dameshek MPD MPN = clonal, hematopoietic stem cell disorders, proliferation in BM of
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationMALATTIE MIELOPROLIFERATIVE CRONICHE
MALATTIE MIELOPROLIFERATIVE CRONICHE Dott. Roberto Latagliata Policlinico Umberto I Università Sapienza, Roma Highlights from EHA 2017: some points to address today WHO 2016 MPN classification: hot topics
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationClinical Perspective The Hematologist s View
SPLANCHNIC VEIN THROMBOSIS. TYPICAL OR ATYPICAL MPN? Giovanni Barosi Unit of Clinical Epidemiology/Center ofr the Study of Myelofibrosis. IRCCS Policlinico S. Matteo Foundation, Pavia Lisbon, 4-5 May 2012
More informationرناد زكريا Dr. ahmad Dr. ahmad. P a g e 1
5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1 Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred
More informationChi sono i candidati agli inibitori di JAK2
Chi sono i candidati agli inibitori di JAK2 Francesco Passamon, Hematology, University Hospital Varese, Italy Ruxoli8nib (US approved in MF; EAP study and compassionate use in Italy) SAR302503 (phase 3
More informationFocus on aggressive polycythemia vera
Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationHuman Genetics 542 Winter 2018 Syllabus
Human Genetics 542 Winter 2018 Syllabus Monday, Wednesday, and Friday 9 10 a.m. 5915 Buhl Course Director: Tony Antonellis Jan 3 rd Wed Mapping disease genes I: inheritance patterns and linkage analysis
More informationMutations in MPN: Hereditary Predispositions, Disease Initiators and Drivers of Progression
Mutations in MPN: Hereditary Predispositions, Disease Initiators and Drivers of Progression Robert Kralovics, PhD CeMM - Center for Molecular Medicine of the Austrian Academy of Sciences Vienna, Austria
More informationHematologic Malignancies
Hematologic Malignancies Tiziano Barbui Ayalew Tefferi Editors Myeloproliferative Neoplasms Critical Concepts and Management Editors Prof. Dr. Tiziano Barbui Research Foundation Ospedale Maggiore (FROM)
More informationHuman Genetics 542 Winter 2017 Syllabus
Human Genetics 542 Winter 2017 Syllabus Monday, Wednesday, and Friday 9 10 a.m. 5915 Buhl Course Director: Tony Antonellis Module I: Mapping and characterizing simple genetic diseases Jan 4 th Wed Mapping
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationGeorge R. Honig Junius G. Adams III. Human Hemoglobin. Genetics. Springer-Verlag Wien New York
George R. Honig Junius G. Adams III Human Hemoglobin Genetics Springer-Verlag Wien New York George R. Honig, M.D., Ph.D. Professor and Head Department of Pediatrics, College of Medicine University of Illinois
More informationCLINICAL CASE PRESENTATION
European Winter School of Internal Medicine 2015 Riga, Latvia, 26-30 January CLINICAL CASE PRESENTATION Vasiliy Chulkov South Ural State Medical University (Chelyabinsk, Russia) CHELYABINSK CLINICAL HISTORY
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationEvaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-PCR
Original Article Evaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-CR Karimzadeh. 1 M.Sc, Ghaffari.SH 2 h.d, Chahardouli.B 2 M.Sc,Zaghal.A 1 M.Sc, Einollahi.N 1 h.d, Mousavi.SA
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
More informationProblem set questions from Final Exam Human Genetics, Nondisjunction, and Cancer
Problem set questions from Final Exam Human Genetics, Nondisjunction, and ancer Mapping in humans using SSRs and LOD scores 1. You set out to genetically map the locus for color blindness with respect
More informationIntro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia
Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro
More informationMyeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination
Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Arati V. Rao, M.D. Division of Medical Oncology and Geriatrics Duke University Medical Center Durham
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationSupplementary information. Supplementary figure 1. Flow chart of study design
Supplementary information Supplementary figure 1. Flow chart of study design Supplementary Figure 2. Quantile-quantile plot of stage 1 results QQ plot of the observed -log10 P-values (y axis) versus the
More informationManaging ET in Tiziano Barbui MD
Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationMPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs
MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationIs the recommended hematocrit target in polycythemia vera evidence based? Tiziano BARBUI, MD Ospedali Riuniti, Bergamo, Italy
Is the recommended hematocrit target in polycythemia vera evidence based? Tiziano BARBUI, MD Ospedali Riuniti, Bergamo, Italy We have generated a transgenic mouse line that reaches a hematocrit concentration
More informationTheme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -
Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects - Professor Yutaka YATOMI, M.D., Ph.D., The Department of Clinical Laboratory Medicine,
More informationIncreased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients
Brief Report Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients Elisa Rumi, 1 Francesco Passamonti, 1 Chiara Elena, 1 Daniela Pietra, 1 Luca Arcaini,
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationLecture 17: Human Genetics. I. Types of Genetic Disorders. A. Single gene disorders
Lecture 17: Human Genetics I. Types of Genetic Disorders A. Single gene disorders B. Multifactorial traits 1. Mutant alleles at several loci acting in concert C. Chromosomal abnormalities 1. Physical changes
More informationRelated Policies None
Medical Policy MP 2.04.60 BCBSA Ref. Policy: 2.04.60 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationBone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany
Bone marrow histopathology in Ph - CMPDs - the new WHO classification - Juergen Thiele Cologne, Germany Current issues in MPNs concerning morphology 1.Prodromal stages of disease 2.Impact of histopathology
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationThe role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms
Original Articles The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms Damla Olcaydu, 1 * Elisa Rumi, 2 * Ashot Harutyunyan 1, Francesco Passamonti, 2 Daniela
More informationSingle Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions
Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are
More informationSequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
/, 017, Vol. 8, (No. 0), pp: 33416-3341 Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms Chiara Cavalloni 1,*, Elisa Rumi 1,,*, Virginia V. Ferretti, Daniela Pietra,
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationEmerging diagnostic and risk stratification criteria
PV STATE OF MIND Polycythemia vera: Emerging diagnostic and risk stratification criteria Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida Disclosure These slides were developed by Incyte Corporation
More informationRESPONSE (NCT )
Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian
More information3. Pardanani A, et al. Leukemia 2009;23: Hedvat M, et al. Cancer Cell 2009;16:
A Phase / Study of NS-8, an Oral JAK Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (ppv MF), or Post-Essential Thrombocythemia Myelofibrosis (pet MF) 8 Srdan
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationHow to monitor MPN patients
How to monitor MPN patients MPN carries significant burden and risk Transformation to MF or AML 1 Neurological complications 2 MPN-associated general symptoms (eg, pruritus, fatigue) 3 Microvascular symptoms
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationWHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand
WHO 2016/17 update on Myeloproliferative Neoplasms Anna Ruskova Auckland City Hospital New Zealand BLOOD, 19 MAY 2016 x VOLUME 127, NUMBER 20 2 2016/17 Classification of Myeloproliferative Neoplasms Chronic
More informationChapt 15: Molecular Genetics of Cell Cycle and Cancer
Chapt 15: Molecular Genetics of Cell Cycle and Cancer Student Learning Outcomes: Describe the cell cycle: steps taken by a cell to duplicate itself = cell division; Interphase (G1, S and G2), Mitosis.
More informationLatest updates in Myeloproliferative Neoplasms. Elizabeth Hexner, MD, MSTR
Latest updates in Myeloproliferative Neoplasms Elizabeth Hexner, MD, MSTR Disclosures Nothing to disclose Agenda/Goals Treatment goals in PV Indications for cytoreduction in patients polycythemia vera
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationFerrata Storti Foundation
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype Somatic mutations in JAK2, CALR and MPL are found in the majority of myeloproliferative
More informationA. ILEA 1* A. M. VLADAREANU 2 E. NICULESCU-MIZIL 3
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 9 (58) No. 1-2016 THE SIMULTANEOUS OCCURRENCE OF THE BCR-ABL TRANSLOCATION AND THE Jak2V617F MUTATION. DETECTION AND DYNAMICS
More informationNon-Mendelian inheritance
Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University
More informationDecreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients
Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients H.-H. Hsiao 1,2, Y.-C. Liu 1,2, M.-Y. Yang 3, Y.-F. Tsai 2, T.-C. Liu 1,2, C.-S. Chang 1,2 and S.-F. Lin 1,2 1 Faculty of Medicine,
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationCOEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?
COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE? M. DE SLOOVERE (1), L. HARLET (2), S. VAN STEENWEGHEN (3), E. MOREAU (1), D. DE SMET (1) (1) DEPARTMENT OF LABORATORY MEDICINE,
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 4 FEBRUARY 1 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates
More informationMutational Analysis of EXON 9 of the CALR Gene (Reference )
Mutational Analysis of EXON 9 of the CALR Gene (Reference 2014.01.002) Notice of Assessment June 2014 DISCLAIMER: This document was originally drafted in French by the Institut national d'excellence en
More informationBrief Communication Diagnostic Hematology
Brief Communication Diagnostic Hematology Ann Lab Med 2015;35:233-237 http://dx.doi.org/10.3343/alm.2015.35.2.233 ISSN 2234-3806 eissn 2234-3814 Incidence, Clinical Features, and Prognostic Impact of CALR
More informationThe myeloproliferative neoplasms polycythemia vera, essential
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Myeloproliferative Neoplasms Jerry L. Spivak, M.D. From the Hematology Division, Department of Medicine, Johns Hopkins University
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationHow to treat non-clonal polyglobulia: to bleed or not to bleed. Claire Harrison Guy s and St Thomas Hospitals London, UK
How to treat non-clonal polyglobulia: to bleed or not to bleed Claire Harrison Guy s and St Thomas Hospitals London, UK Disclosures Institutional research support: Novartis and Shire Pharmaceuticals Speaker:
More informationChronic Myeloproliferative Disorders
1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationGenetics Mutations 2 Teacher s Guide
Genetics Mutations 2 Teacher s Guide 1.0 Summary Mutations II is an extension activity, which reviews and enhances the previous Core activities. We recommend that it follow Mutations and X-Linkage. This
More informationMultifactorial Inheritance. Prof. Dr. Nedime Serakinci
Multifactorial Inheritance Prof. Dr. Nedime Serakinci GENETICS I. Importance of genetics. Genetic terminology. I. Mendelian Genetics, Mendel s Laws (Law of Segregation, Law of Independent Assortment).
More informationPhenotype analysis in humans using OMIM
Outline: 1) Introduction to OMIM 2) Phenotype similarity map 3) Exercises Phenotype analysis in humans using OMIM Rosario M. Piro Molecular Biotechnology Center University of Torino, Italy 1 MBC, Torino
More informationThe prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
Received: 3 February 2017 Revised: 13 February 2017 Accepted: 14 February 2017 DOI: 10.1002/ajh.24689 RESEARCH ARTICLE The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin
More informationThe Genetics of VHL. Proper tissue growth - controlled traffic. How human cells and tissue grow and die?
How human cells and tissue grow and die? The Genetics of VHL Xia Wang MD PhD Oct, 2017 Proper tissue growth - controlled traffic Normal tissue growth is regulated by many genetic factors Safe traffic is
More informationTHE ITALIAN EXPERIENCE
MYELOFIBROSIS THE ITALIAN EXPERIENCE Giovanni Barosi IRCCS Policlinico S. Matteo. Pavia. Italy Angers, 1-3 October 2004 Myelofibrosis in the eighties A poorly characterized biological syndrome Heterogeneity
More informationDan Koller, Ph.D. Medical and Molecular Genetics
Design of Genetic Studies Dan Koller, Ph.D. Research Assistant Professor Medical and Molecular Genetics Genetics and Medicine Over the past decade, advances from genetics have permeated medicine Identification
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More information